(Q36058584)

English

Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma (English)

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

author name string

Robert Chen

1

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Joycelynne M Palmer

2

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Sandra H Thomas

3

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Ni-Chun Tsai

4

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Len Farol

5

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Auayporn Nademanee

6

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Stephen J Forman

7

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Ajay K Gopal

8

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

language of work or name

0 references

publication date

18 May 2012

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

119

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

26

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

6379-6381

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383201

2 October 2017

Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383201

2 October 2017

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383201

2 October 2017

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383201

2 October 2017

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383201

2 October 2017

Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383201

2 October 2017

CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383201

2 October 2017

Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383201

2 October 2017

Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383201

23 September 2018

Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383201

23 September 2018

Revised response criteria for malignant lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383201

23 September 2018

Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula

1 reference

https://pubmed.ncbi.nlm.nih.gov/22611160

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2012-03-418673

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36058584&oldid=1994790278"